Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 80 Debt-to-EBITDA is 0.09 as of Dec. 2025, which is 84% below its 10-year median of 0.58. GuruFocus rates DIUXF with a GF Score™ of 80/100 and a GF Value™ of $2.05 (Fairly Valued). The stock has 1 warning sign investors should review. Among 478 Healthcare Providers & Services companies, Diaceutics ranks better than 88.91% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Diaceutics's Debt-to-EBITDA or its related term are showing as below:
DIUXF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.11 Med: 0.58 Max: 2.89
Current: 0.19
During the past 10 years, the highest Debt-to-EBITDA Ratio of Diaceutics was 2.89. The lowest was 0.11. And the median was 0.58.
DIUXF's Debt-to-EBITDA is ranked better than 88.91% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs DIUXF: 0.19
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Diaceutics Debt-to-EBITDA Related Terms
Diaceutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Diaceutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DIUXF vs VEEV, BTSG, TEM: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, Diaceutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diaceutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Diaceutics (DIUXF) has a Debt-to-EBITDA of 0.09 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Diaceutics. This is 84% below median its historical median of 0.58. Over the past decade, Diaceutics' Debt-to-EBITDA has ranged from 0.11 to 2.89. According to the industry distribution chart, Diaceutics ranks #53 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 11.1%.
Is Diaceutics' Debt-to-EBITDA too high?
Diaceutics' current Debt-to-EBITDA of 0.09 is 84% below median its 10-year median of 0.58. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 2.89. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. Diaceutics' value of 0.09 is 96% below this industry median. Based on the distribution chart, Diaceutics ranks #53 out of 478 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Diaceutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #53 out of 478 companies for Debt-to-EBITDA. This places Diaceutics in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.25. Diaceutics' value of 0.09 is 96% below this benchmark. Historically, Diaceutics' own Debt-to-EBITDA has ranged from 0.11 to 2.89 over the past decade. While the company's 10-year median is 0.58 vs. the industry median of 2.25, Diaceutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current Debt-to-EBITDA of 0.09 is 96% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Diaceutics. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current Debt-to-EBITDA is 0.09, which is 84% below median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (DIUXF) is currently considered Fairly Valued. The stock's GF Value™ is $2.05, compared to a current price of $2.00 — trading 2.4% below its estimated fair value. The current Debt-to-EBITDA is 0.09, which is 84% below median its 10-year median of 0.58 and 96% below the Healthcare Providers & Services industry median of 2.25. Diaceutics' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Diaceutics (DIUXF), the current Debt-to-EBITDA is 0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 2.4% below its estimated GF Value™ of $2.05.
GuruFocus considers Diaceutics to be Fairly Valued.
Key valuation signals for DIUXF:
Debt-to-EBITDA: 0.09 (84% below median its 10-year median of 0.58)
GF Value™: $2.05 vs. price of $2.00 (2.4% below fair value)
Industry Position: 96% below the Healthcare Providers & Services median (#53 of 478)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score
Get the complete analysis for DIUXF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
